Active Biotech's President & CEO Sven Andréasson and
CFO Hans Kolam present and comment on the quarterly report January-March 2003.
To participate in the teleconference, please visit http://213.86.178.134/inv/reg.html?Acc=4733091300&Conf=127301 for instructions.
To participate in the teleconference, please visit http://213.86.178.134/inv/reg.html?Acc=4733091300&Conf=127301 for instructions.
To listen and to view the presentation: please visit www.activebiotech.com.
To listen to the conference and to view the presentation afterwards, please call +44 20 8288 4459, password 165272 and/or visit www.activebiotech.com.
Active Biotech
AB is a biotechnology company focusing on research in and development of pharmaceuticals. Active Biotech has a strong R&D portfolio and pipeline products with focus primarily on autoimmune/inflammatory diseases and cancer. Most advanced projects include orally administered small molecules with unique immunomodulatory properties that can be used to treat autoimmune and inflammatory diseases (SAIK), as well as a novel concept for use in cancer immunotherapy (TTS).
Active Biotech AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50
e-mail info@activebiotech.com